首页> Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie> A novel missense mutation Smad4 V354L enhances the efficacy of docetaxel in non-small cell lung cancer.

A novel missense mutation Smad4 V354L enhances the efficacy of docetaxel in non-small cell lung cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Xia,Xue

第一单位： Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, 250033, China.

作者： Xia,Xue ^[1] ; Yongjia,Zhou ^[2] ; Huiping,Liu ^[3] ; Yan,Gao ^[1] ; Xinyu,Ma ^[1] ; Zhaohua,Xiao ^[2] ; Wenhao,Zhang ^[2] ; Peichao,Li ^[4] ; Zhongxian,Tian ^[4] ; Yun,Luan ^[5] ; Xiaogang,Zhao ^[6]

作者单位： Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, 250033, China. ^[1] Department of Thoracic Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, 250033, China. ^[2] School of Pharmacy, Yantai University, Yantai 264005, China. ^[3] Department of Thoracic Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, 250033, China; Key Laboratory of Thoracic Cancer in Universities of Shandong, The Second Hospital, Cheeloo College of Medicine, Shandong University, 250033, China. ^[4] Central Laboratory, Institute of Medical Science, The Second Hospital, Cheeloo College of Medicine, Shandong University, 250033, China. ^[5] Department of Thoracic Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, 250033, China; Key Laboratory of Thoracic Cancer in Universities of Shandong, The Second Hospital, Cheeloo College of Medicine, Shandong University, 250033, China. Electronic address: zhaoxiaogang0621@163.com. ^[6]

关键词 Docetaxel Next-generation sequencing Non-small cell lung cancer Novel missense mutation Prognosis Smad4 V354L